BriaCell Therapeutics Corp. (BCTXW) P/E Ratio History
Deep ValueTrading at 0.0x · of 5-year range · Significant discount to historical valuation · Data 2022–2022
Loading P/E history...
P/E Ratio Analysis
As of June 30, 2026, BriaCell Therapeutics Corp. (BCTXW) trades at a price-to-earnings ratio of 0.0x, with a stock price of $0.00 and trailing twelve-month earnings per share of $-13.93.
The current P/E is 100% below its 5-year average of 25.7x. Over the past five years, BCTXW's P/E has ranged from a low of 3.1x to a high of 68.4x, placing the current valuation at the nullth percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.9x, BCTXW trades at a 100% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.6x.
Relative to the broader market, BCTXW trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCTXW DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BCTXW Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BCTXW P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $9B | 30.1Lowest | 1.31Best | -25%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BCTXW Historical P/E Data (2022–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q3 | Apr 30 2022 | $3.50 | $0.64 | 5.5x | -79% |
| FY2022 Q2 | Jan 31 2022 | $3.02 | $0.98 | 3.1x | -88% |
| FY2022 Q1 | Oct 31 2021 | $4.65 | $0.07 | 68.4x | +167% |
Average P/E for displayed period: 25.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCTXW — Frequently Asked Questions
Quick answers to the most common questions about buying BCTXW stock.
What is BCTXW's P/E ratio?
BriaCell Therapeutics Corp. (BCTXW) trailing twelve-month P/E ratio is 0.0x, based on TTM diluted EPS of $-13.93. The 5-year average P/E is 25.7x and the historical range spans 3.1x to 68.4x.
Is BCTXW stock overvalued or undervalued?
BCTXW current P/E: 0.0x. 5-year average P/E: 25.7x. Percentile: N/A.
Is BCTXW stock expensive?
BCTXW is fairly valued relative to its own history. The current P/E of 0.0x is near the 5-year average of 25.7x (N/A percentile of historical range).
What is BCTXW's historical P/E range?
Over the past 5 years, BCTXW's P/E ratio has ranged from 3.1x to 68.4x, with a median of 5.5x and an average of 25.7x. The current P/E of 0.0x places the stock at the N/A percentile of this range. Full historical data spans 2022–2022.
How does BCTXW's P/E compare to the S&P 500?
BCTXW current P/E: 0.0x. S&P 500 median P/E: 25.1x.
How does BCTXW's valuation compare to Healthcare peers?
BriaCell Therapeutics Corp. P/E of 0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is BCTXW's PEG ratio?
BCTXW PEG ratio is N/A, based on a P/E of 0.0x and EPS growth of -45.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BCTXW's earnings yield?
BCTXW earnings yield is N/A, the inverse of its 0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.